ALKS:NASDAQ
Alkermes Plc
$46.18
arrow_downward
-1.43%(-0.67) 1D
$46.18
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 19, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$46.90
High
$47.26
Low
$45.74
Mkt. cap
7.76B
Avg. vol.
1.77M
Volume
0.00
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
Open
$46.90
High
$47.26
Low
$45.74
Mkt. cap
7.76B
Avg. vol.
1.77M
Volume
0.00
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
Nvidia Has Lost More Than the Market Value of 495 S&P 500 Companies in 6 Weeks -- and Its Downtrend May Be Just Beginning
MarketWatch
·
12 minutes ago
Here’s what happened next after previous times the S&P 500 losing streak reached six sessions
MarketForces Africa
·
1 hour ago
S&P 500, Nasdaq, Dow Jones Dip Amidst Anthropic IPO Debut
Investing.com
·
2 hours ago
S&P 500 Breaks Support as Global Risk Sentiment Begins to Crack
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealkermes.com